TransCode Therapeutics ( ($RNAZ) ) just unveiled an update. On January 6, 2026, TransCode Therapeutics announced the publication in the Journal of ...
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the ...
TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive ...
Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced today that its lead therapeutic candidate, TTX-MC138, demonstrated efficacy in preclinical models of glioblastoma multiforme (GBM), the ...
Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma. TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead ...
UNIONDALE, NY / ACCESS Newswire / January 6, 2026 / Marquis Who's Who honors Jason A. Marks, MBA-HCM, for his expertise in ...
VANCOUVER, BC / ACCESS Newswire / January 6, 2026 / Pathfinder Ventures Inc. (the "Company") announces the results of its Annual General and Special Meeting of shareholders (the "Meeting" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback